Combinatorial drug therapy for cancer in the post-genomic era

[1]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Christie S. Chang,et al.  The BioGRID interaction database: 2013 update , 2012, Nucleic Acids Res..

[3]  A. Jemal,et al.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. , 2012, The Lancet. Oncology.

[4]  Qian Wang,et al.  Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mallika Singh,et al.  Genetically engineered mouse models: closing the gap between preclinical data and trial outcomes. , 2012, Cancer research.

[6]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[7]  H. Brody.  From an ethics of rationing to an ethics of waste avoidance. , 2012, The New England journal of medicine.

[8]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[9]  Paul Workman,et al.  Personalized medicine: patient-predictive panel power. , 2012, Cancer cell.

[10]  Andrew L. Kung,et al.  Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. , 2012, Cancer cell.

[11]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[12]  D. Berry.  Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.

[13]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[14]  D. Solit,et al.  Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas? , 2012, Clinical Cancer Research.

[15]  S. Lowe,et al.  Life in the Fast Lane: Mammalian Disease Models in the Genomics Era , 2012, Cell.

[16]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[17]  Ben H. Park,et al.  Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood , 2012, Clinical Cancer Research.

[18]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[19]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[20]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[21]  P. Workman,et al.  Discovery of small molecule cancer drugs: Successes, challenges and opportunities , 2012, Molecular oncology.

[22]  Levi A Garraway,et al.  Circumventing cancer drug resistance in the era of personalized medicine. , 2012, Cancer discovery.

[23]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[24]  Michele De Palma,et al.  The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities , 2012, Molecular oncology.

[25]  B. Taylor,et al.  Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF , 2012, Oncogene.

[26]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[27]  P. Workman,et al.  Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. , 2012, Annual review of pharmacology and toxicology.

[28]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[30]  Xing-Ming Zhao,et al.  Prediction of Drug Combinations by Integrating Molecular and Pharmacological Data , 2011, PLoS Comput. Biol..

[31]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[32]  Bissan Al-Lazikani,et al.  canSAR: an integrated cancer public translational research and drug discovery resource , 2011, Nucleic Acids Res..

[33]  W. Pao,et al.  Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer , 2011, Molecular pharmaceutics.

[34]  W. Sellers.  A Blueprint for Advancing Genetics-Based Cancer Therapy , 2011, Cell.

[35]  Lincoln Stein,et al.  Reactome pathway analysis to enrich biological discovery in proteomics data sets , 2011, Proteomics.

[36]  F. Prinz,et al.  Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.

[37]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[38]  Tom L. Blundell,et al.  Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database , 2011, BMC Bioinformatics.

[39]  N. Socci,et al.  Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling , 2011, Science Translational Medicine.

[40]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[41]  E. Ruppin,et al.  Predicting selective drug targets in cancer through metabolic networks , 2011, Molecular systems biology.

[42]  K. Flaherty,et al.  Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Workman,et al.  Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors , 2011, Current medicinal chemistry.

[44]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[45]  A. Tolcher,et al.  A phase I dose-escalation study of oral MK-2206 (allosteric AKT inhibitor) with oral selumetinib (AZD6244; MEK inhibitor) in patients with advanced or metastatic solid tumors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Luay Nakhleh,et al.  Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling , 2011, Oncogene.

[47]  M. Garrett,et al.  Anticancer therapy with checkpoint inhibitors: what, where and when? , 2011, Trends in pharmacological sciences.

[48]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[49]  Sanjay A Pai,et al.  The emperor of all maladies , 2011 .

[50]  J. Woodcock,et al.  Development of novel combination therapies. , 2011, The New England journal of medicine.

[51]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[52]  Julio Saez-Rodriguez,et al.  Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli , 2011, PLoS Comput. Biol..

[53]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[54]  C. Der.  Faculty Opinions recommendation of COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. , 2010 .

[55]  L. Garraway,et al.  Clinical implications of the cancer genome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Michael Peyton,et al.  Combination Treatment with MEK and AKT Inhibitors Is More Effective than Each Drug Alone in Human Non-Small Cell Lung Cancer In Vitro and In Vivo , 2010, PloS one.

[57]  Paul N. Mortenson,et al.  Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. , 2010, Journal of medicinal chemistry.

[58]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[59]  Lincoln Stein,et al.  Reactome: a database of reactions, pathways and biological processes , 2010, Nucleic Acids Res..

[60]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[61]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[62]  V. A. Shiva Ayyadurai,et al.  CytoSolve: A Scalable Computational Method for Dynamic Integration of Multiple Molecular Pathway Models , 2010, Cellular and molecular bioengineering.

[63]  Alan Ashworth,et al.  Translating cancer research into targeted therapeutics , 2010, Nature.

[64]  M. Gerlinger,et al.  How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine , 2010, British Journal of Cancer.

[65]  Yiling Lu,et al.  Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. , 2010, Cancer research.

[66]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[67]  Taebo Sim,et al.  A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. , 2010, Journal of medicinal chemistry.

[68]  Paul Workman,et al.  Envisioning the future of early anticancer drug development , 2010, Nature Reviews Cancer.

[69]  G. Hon,et al.  Next-generation genomics: an integrative approach , 2010, Nature Reviews Genetics.

[70]  G. Shapiro,et al.  A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2 , 2010, Clinical Cancer Research.

[71]  Melanie I. Stefan,et al.  BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models , 2010, BMC Systems Biology.

[72]  Borisas Bursteinas,et al.  ROCK: a breast cancer functional genomics resource , 2010, Breast Cancer Research and Treatment.

[73]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[74]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[75]  C. Ng,et al.  A phase I study of bevacizumab in combination with sunitinib, sorafenib, and erlotinib plus cetuximab, and trastuzumab plus lapatinib. , 2010 .

[76]  J. Baselga,et al.  A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. , 2010 .

[77]  Bo Zhang,et al.  A formal model for analyzing drug combination effects and its application in TNF-α-induced NFκB pathway , 2010, BMC Systems Biology.

[78]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[79]  Mark P Little,et al.  Cancer models, genomic instability and somatic cellular Darwinian evolution , 2010, Biology Direct.

[80]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[81]  F. Michor,et al.  Evolution of resistance to anti-cancer therapy during general dosing schedules. , 2010, Journal of theoretical biology.

[82]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[83]  Jacob J Hughey,et al.  Computational modeling of mammalian signaling networks , 2010, Wiley interdisciplinary reviews. Systems biology and medicine.

[84]  T. Mukohara,et al.  Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  Martin Peifer,et al.  Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling , 2010, PloS one.

[86]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[87]  Gary D Bader,et al.  The Genetic Landscape of a Cell , 2010, Science.

[88]  S. Martino,et al.  Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[89]  R. Bernards,et al.  Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer , 2009, Oncogene.

[90]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[91]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[92]  Livia Perfetto,et al.  MINT, the molecular interaction database: 2009 update , 2009, Nucleic Acids Res..

[93]  Li Wang,et al.  High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) , 2009, Cancer biology & therapy.

[94]  S. Chandarlapaty,et al.  Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth , 2009, Oncogene.

[95]  Irina M. Armean,et al.  The IntAct molecular interaction database in 2010 , 2009, Nucleic Acids Res..

[96]  P. R. ten Wolde,et al.  Spatio-temporal correlations can drastically change the response of a MAPK pathway , 2009, Proceedings of the National Academy of Sciences.

[97]  T. Willson,et al.  Open access chemical and clinical probes to support drug discovery. , 2009, Nature chemical biology.

[98]  Michael J. Emanuele,et al.  A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.

[99]  G. Vassal,et al.  Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. , 2009, Cancer research.

[100]  U. Banerji,et al.  Heat Shock Protein 90 as a Drug Target: Some Like It Hot , 2009, Clinical Cancer Research.

[101]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[102]  Corey Nislow,et al.  Combination chemical genetics. , 2008, Nature chemical biology.

[103]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[104]  M. Esteller,et al.  Epigenetic biomarkers for human cancer: the time is now. , 2008, Critical reviews in oncology/hematology.

[105]  M. Stratton,et al.  Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing , 2008, Proceedings of the National Academy of Sciences.

[106]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  L. Pearl,et al.  NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. , 2008, Cancer research.

[108]  L. Pearl,et al.  The Hsp90 molecular chaperone: an open and shut case for treatment. , 2008, The Biochemical journal.

[109]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[110]  A. Ashworth,et al.  Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. , 2008, Cancer cell.

[111]  C. Keith,et al.  The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. , 2007, Cancer research.

[112]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[114]  Forest M White,et al.  Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma , 2007, Proceedings of the National Academy of Sciences.

[115]  A. Ashworth,et al.  Utilizing RNA interference to enhance cancer drug discovery , 2007, Nature Reviews Drug Discovery.

[116]  Pall I. Olason,et al.  A human phenome-interactome network of protein complexes implicated in genetic disorders , 2007, Nature Biotechnology.

[117]  P. Lønning,et al.  Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial , 2007, The Lancet.

[118]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[119]  K. Shokat,et al.  Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.

[120]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[121]  Madhusudan Natarajan,et al.  A global analysis of cross-talk in a mammalian cellular signalling network , 2006, Nature Cell Biology.

[122]  Y. Bang,et al.  Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.

[123]  K. Sachs,et al.  Causal Protein-Signaling Networks Derived from Multiparameter Single-Cell Data , 2005, Science.

[124]  M. Kris,et al.  Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel , 2005, Clinical Cancer Research.

[125]  P. Workman,et al.  The combination of cytotoxic and molecularly targeted therapies - can it be done? , 2004 .

[126]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[127]  T. Hunter,et al.  Inappropriate Activation of the TSC/Rheb/mTOR/S6K Cassette Induces IRS1/2 Depletion, Insulin Resistance, and Cell Survival Deficiencies , 2004, Current Biology.

[128]  Armando Santoro,et al.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.

[129]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[130]  J. Kornhauser,et al.  PhosphoSite: A bioinformatics resource dedicated to physiological protein phosphorylation , 2004, Proteomics.

[131]  M. Hung,et al.  The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells , 2004, Cancer Research.

[132]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[133]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[134]  Michael I. Jordan,et al.  Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[135]  D. Wodarz,et al.  Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy. , 2003, Cancer research.

[136]  J. Kuriyan,et al.  Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.

[137]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[138]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[139]  Gabriele Ausiello,et al.  MINT: the Molecular INTeraction database , 2006, Nucleic Acids Res..

[140]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[141]  R. Wooster,et al.  Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. , 2001, Biochemical pharmacology.

[142]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[143]  D. Tuveson,et al.  Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.

[144]  Ennis,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[145]  S. Huang,et al.  Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. , 2000, Experimental cell research.

[146]  A. Khomenko,et al.  Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.

[147]  T G Myers,et al.  DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. , 1999, Journal of the National Cancer Institute.

[148]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[149]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[150]  M. Berenbaum.  The expected effect of a combination of agents: the general solution. , 1985, Journal of theoretical biology.

[151]  R. Jackson,et al.  Kinetic simulation of anticancer drug interactions. , 1980, International journal of bio-medical computing.

[152]  Goldie Jh,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .

[153]  R T Schimke,et al.  Gene amplification and drug resistance in cultured murine cells. , 1978, Science.

[154]  R L Juliano,et al.  A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.

[155]  R C Young,et al.  Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer , 1975, Cancer.

[156]  S. Loewe,et al.  Die quantitativen Probleme der Pharmakologie , 1928 .

[157]  D. Lauffenburger,et al.  Comparing Signaling Networks between Normal and Transformed Hepatocytes Using Discrete Logical Models , 2011 .

[158]  A. Kibel.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study: Scher HI, the Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium (Memorial Sloan-Kettering Cancer Ctr, NY; et al) Lancet 375:1437-1446, 2010 § , 2011 .

[159]  Razelle Kurzrock,et al.  Combining targeted therapies: practical issues to consider at the bench and bedside. , 2010, The oncologist.

[160]  J. Salk.  Clonal evolution in cancer , 2010 .

[161]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[162]  Raymond A. Molnar,et al.  Molecular Systems Biology 3; Article number 80; doi:10.1038/msb4100116 Citation: Molecular Systems Biology 3:80 , 2022 .

[163]  E. Petricoin,et al.  Modeling of protein signaling networks in clinical proteomics. , 2005, Cold Spring Harbor symposia on quantitative biology.

[164]  B. Stockwell,et al.  Multicomponent therapeutics for networked systems , 2005, Nature Reviews Drug Discovery.

[165]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[166]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[167]  Adam J. Smith,et al.  The Database of Interacting Proteins: 2004 update , 2004, Nucleic Acids Res..

[168]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[169]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[170]  Ioannis Xenarios,et al.  DIP: The Database of Interacting Proteins: 2001 update , 2001, Nucleic Acids Res..

[171]  A. D. Lunn,et al.  The Data Sets , 1994 .

[172]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[173]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.

[174]  R. Jackson,et al.  Enzyme kinetics and combination chemotherapy: an appraisal of current concepts. , 1975, Advances in enzyme regulation.

[175]  R. W. Brockman,et al.  MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS. , 1963, Advances in cancer research.